Continuous infusion of granulocyte colony-stimulating factor is associated with an advantage in neutrophil recovery in pediatric oncologic disorders.
Cancer Chemother PharmacolOct 3, 2026 (epub)
Yi-Lun Wang, Tsung-Yen Chang, Shih-Hsiang Chen et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the effects of continuous infusion versus injection of granulocyte colony-stimulating factor (G-CSF) on neutrophil recovery in 20 pediatric oncology patients. The study found that the intravenous drip (IVD) group had a mean recovery time of 6.2 days compared to 7.6 days for the intravenous injection (IVI) group (P = 0.0068).
Key findings
- Mean duration from CIN to neutrophil recovery was 6.2 days for IVD vs. 7.6 days for IVI (P = 0.0068).
- The IVD group had a lower incidence of febrile neutropenia at 15% compared to 50% in the IVI group (P = 0.0407).
- Adverse effects were comparable between the IVD and IVI groups.
Why it matters
The findings suggest that the IVD route of G-CSF administration may enhance neutrophil recovery and reduce febrile neutropenia risk, which is critical in managing chemotherapy-induced neutropenia in pediatric oncology patients.